Elotuzumab is a humanized IgG1 mAb targeting SLAMF7, a surface marker co-expressed with CD38 on most MM cells, enhancing NK cell-mediated cytotoxicity.124,125. Here, SLAMF7 is linked to Miyoshi myopathy.